Effect of DASH Diet and Progressive Muscle Relaxation on Cardiovascular Risks in Postmenopausal Women
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: DASH diet, Progressive muscle relaxation, Anti hypertensive drugs.
- Who it may be relevant to
- Registry conditions: Cardiovascular Complication. Basic parameters: 50 years — 60 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study will be conducted to investigate the effect of DASH diet and Progressive muscle relaxation on cardiovascular risks in postmenopausal women.
Detailed description
Cardiovascular disease is the leading cause of morbidity and mortality in men and women, but the incidence of cardiovascular disease related deaths is higher in women than men. Hypertension is one of the leading risk factors for cardiovascular disease. Aging in both men and women is characterized by increases in blood pressure (BP), but the age-related increases are more rapid in women particularly postmenopausal women than in men.
A variety of non-pharmacologic treatments to manage stress have been found effective in reducing blood pressure and the development of hypertension. The DASH eating pattern promotes blood pressure reduction by encouraging the consumption of foods that are low in saturated fat, total fat, cholesterol, and sodium and high in potassium, calcium, magnesium, fiber, and protein. In terms of actual food choices, the DASH eating pattern encourages whole grains, fat free or low-fat dairy products, fruits, vegetables, poultry, fish, and nuts. Foods that are limited include fatty meats, full-fat dairy products, tropical oils (e.g., coconut, palm, and palm kernel oils), and sweets and sugar sweetened beverages.
The mechanism by which relaxation techniques lower blood pressure is unclear. One theory suggests that they may help lower the stress and physiologic arousal produced by the autonomic nervous system, thereby reducing blood pressure. So this study is a trial to determine the effect of DASH diet and progressive muscle relaxation in reducing cardiovascular risks in postmenopausal women.
Interventions
- Dietary supplement DASH diet
The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs. - Other Progressive muscle relaxation
The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs. - Drug Anti hypertensive drugs
All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
Primary outcome measures
- Systolic blood pressure [Time frame: 3 months]
- Diastolic blood pressure [Time frame: 3 months]
- Low density lipoprotein [Time frame: 3 months]
- High density lipoprotein [Time frame: 3 months]
- Triglyceride level [Time frame: 3 months]
- Total cholesterol level [Time frame: 3 months]
Secondary outcome measures (1)
- Stress measurement [Time frame: 3 months]
Eligibility criteria
Inclusion criteria
- The participant's ages will be ranged from 50- 60 years old.
- Their body mass index will be ranged from 30-35 kg/m2.
- All women are hypertensive at least one year postmenopause.
- Their scores in perceived stress scale will be ranged from 14-40.
Exclusion criteria
- Women with systolic blood pressure (SBP) >160 mmHg or diastolic blood pressure (DBP) >100mmHg.
- Women who have other known causes of hypertension, such as renal diseases.
- Women who are using sedatives or tranquilizer or antidepressant drugs.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Farahnaz Ahmed Mohamed — Suez
Identifiers
NCT: NCT06600347 · P.T.REC/012/004059